Ubs Group Ag Cure Vac N.V. Transaction History
Ubs Group Ag
- $555 Billion
- Q2 2025
A detailed history of Ubs Group Ag transactions in Cure Vac N.V. stock. As of the latest transaction made, Ubs Group Ag holds 242,090 shares of CVAC stock, worth $1.32 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
242,090
Previous 843,193
71.29%
Holding current value
$1.32 Million
Previous $2.34 Million
43.73%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding CVAC
# of Institutions
103Shares Held
14.2MCall Options Held
270KPut Options Held
114K-
Black Rock Inc. New York, NY2.25MShares$12.3 Million0.0% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ1.97MShares$10.8 Million0.58% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.57MShares$8.58 Million10.6% of portfolio
-
Qube Research & Technologies LTD London, X01.18MShares$6.47 Million0.01% of portfolio
-
Water Island Capital LLC New York, NY957KShares$5.23 Million1.03% of portfolio
About CureVac N.V.
- Ticker CVAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,467,008
- Market Cap $1.03B
- Description
- CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...